LouisianaLouisiana board reviews drug prices and manufacturers report increases
If a related law takes effect, Louisiana’s board will review selected drug prices, and manufacturers will report prices and certain large increases beginning January 1, 2027.
What it does
A state board reviews selected drug prices, reports on drugs it finds excessively costly, and may recommend ways to lower costs while preserving access to care. These rules take effect only if a related law takes effect.
For up to 10 selected drugs, manufacturers report price increases, company research and development spending, and reasons for price changes; the board publishes a yearly report. These rules depend on a related law taking effect.
Manufacturers report current drug prices each year. For certain large increases in drugs costing at least $100 for a 30-day supply, they report the reasons and other company details; the state publishes price information online. These rules depend on a related law taking effect.
Argument forPublic price information and reports could help patients and lawmakers see large drug price increases and the reasons manufacturers give for them.
Argument againstManufacturers may face added reporting work, while limits on what the state can publish could leave patients with less detail about the reasons for price increases.
More detail
The Prescription Drug Affordability Board reviews selected drug prices and reports its findings to lawmakers and the public. The board is within the Louisiana Department of Insurance and includes state officials and appointed public members with significant health or pharmacy experience. The board may recommend ways to lower costs while maintaining access to and the quality of care. These provisions take effect only if Section 7 of Senate Bill 387 of 2026 is enacted and becomes effective. The board reviews its critical drug list at least once every three years and reports to lawmakers each year, at least 60 days before the regular session begins.
Manufacturers report price and company information to the board, which publishes annual reports. The board selects up to 10 drugs each year on which Louisiana spends significant health care dollars after counting rebates. The board selects drugs from different drug classes and may include generic drugs. The information manufacturers submit under this reporting duty is exempt from public inspection and copying. These provisions take effect only if Section 7 of Senate Bill 387 of 2026 is enacted and becomes effective. The board identifies drugs by June 1 and publishes its report by December 31 each year.
Manufacturers report current drug prices and certain large price increases to the state, which publishes price information online. The annual price report covers FDA-approved prescription drugs the manufacturer sells in or into Louisiana. Extra reports include the increase’s causes; annual reports also include company research costs and names of recently approved drugs and drugs that recently lost patent exclusivity. Extra reporting applies when a drug that cost at least $100 for a 30-day supply before the increase rises by at least 40% over the prior three calendar years or at least 15% in the prior calendar year. A manufacturer that corrects a deficient report within 45 days after notice cannot be fined for that reporting failure. The Department may assess penalties of up to $1,000 per day for each violation. These provisions take effect only if Section 7 of Senate Bill 387 of 2026 is enacted and becomes effective. Current price information is due by January 15 each year. A report about a covered increase is due within 30 days after it takes effect, and the state publishes increase information within 60 days of receiving the report.
Where do you stand?
Choose your position
Tell your reps
Take a position to see your representatives and ways to contact them.
Where it stands
- Introduced
- Passed Senate
- Passed House
- To Governor
- Became Law
Looking ahead
No hearings or votes scheduled.
History
- 2026
- Jun 12Signed by the Governor Jeff Landry. Becomes Act No. 915.Became Law
- Jun 12Effective date: See Act.
- Jun 1Enrolled. Signed by the President of the Senate.To Governor
- Jun 1Signed by the Speaker of the House.
- Jun 1Sent to the Governor by the Secretary of the Senate on 6/2/2026.Minor
- May 31Conference Committee Report read, roll called, yeas 89, nays 6. The Conference Committee Report was adopted.
- Vote recorded ADOPT CONFERENCE REPORT (#1801). Result: pass.Lower
- May 31Notice House adopted the Conference Committee Report.
- May 29Conference Committee report received. Lies over under the rules.
- Vote recorded ADOPT (#1576). Result: pass.Upper
- May 29Rules suspended.
- May 29Conference Committee Report read; adopted by a vote of 36 yeas and 0 nays.
- May 29Notice of Senate adoption of Conference Committee Report.
- May 29Scheduled for floor debate on 05/31/2026.
- May 27Notice House Conference Committee members appointed.
- May 26Notice of Senate rejecting House amendments.
- May 26Senate conference committee members appointed: Talbot, Bass, and Myers.
- May 26House conferees appointed: Chance Henry, Firment, and Miller.
- May 26Notice of Senate conferees appointed.
- May 25Amendments proposed by the House read and rejected by a vote of 36 yeas and 0 nays.
- Vote recorded REJECT (#1184). Result: pass.Upper
- May 19Read third time by title, amended, roll called on final passage, yeas 96, nays 0. Finally passed, ordered to the Senate.Passed House
- Vote recorded FINAL PASSAGE (#1382). Result: pass.Lower
- May 19Received from the House with amendments.Minor
- May 18Read by title, amended, passed to 3rd reading.Minor
- May 18Scheduled for floor debate on 05/19/2026.
- May 13Reported without Legislative Bureau amendments.
- May 12Reported with amendments (13-0). Referred to the Legislative Bureau.Minor
- May 5Read by title, amended, recommitted to the Committee on House and Governmental Affairs.
- Apr 29Reported with amendments (11-0). To be recommitted to the Committee on House and Governmental Affairs.Minor
- Apr 21Read by title, under the rules, referred to the Committee on Insurance.Minor
- Apr 20Received in the House from the Senate, read by title, lies over under the rules.
- Apr 15Called from the Calendar.
- Vote recorded FINAL PASSAGE (#359). Result: pass.Upper
- Apr 15Senate floor amendments read and adopted. Read by title and passed by a vote of 37 yeas and 0 nays; ordered reengrossed and sent to the House. Motion to reconsider tabled.Passed Senate
- Apr 8Read by title and returned to the Calendar, subject to call.
- Apr 7Read by title. Committee amendments read and adopted. Ordered engrossed and passed to third reading and final passage.
- Apr 1Reported with amendments.Minor
- Mar 9Introduced in the Senate; read by title. Rules suspended. Read second time and referred to the Committee on Insurance.Minor
- Feb 27Prefiled and under the rules provisionally referred to the Committee on Insurance.Introduced
HealthcareConsumer ProtectionGovernment & Ethics